Opus Genetics is advancing clinical programs for inherited retinal diseases, specifically targeting LCA5 and BEST1 mutations. The company recently announced FDA alignment on a Phase 3 trial design for OPGx-LCA5 and provided a timeline for OPGx-BEST1 results. These gene therapy programs aim to address the underlying genetic causes of rare vision loss.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.